

PATENT
Docket No.: 28110/35761A**REMARKS**

Upon entry of the foregoing amendments, claims 1-32 are under consideration and pending in the application.

The Examiner requires restriction pursuant to 35 U.S.C §121 of one of the 16 groups of inventions. Therefore, in response to the November 19, 2003 Restriction Requirement, Applicants elect *without traverse* Group 4 drawn to an isolated polypeptide with NDPase activity and a composition comprising said polypeptide. Applicants make this election without prejudice to pursuing non-elected subject matter in later applications. Pursuant to 37 CFR 1.141, upon the allowance of the product claims, Applicants respectively reserve the right of rejoinder of Group 4, claims 12-14. and 16, and Group 14, claims 29 and 32 drawn to a method of treatment using said polypeptide. In addition, no change in inventorship under 37 C.F.R. §1.48(b) is merited and as such, no request under 37 C.F.R. §1.48(b) or fee under 37 C.F.R. §1.17(i) are submitted.

CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants respectfully submit that the pending claims are in condition for allowance, and a Notice of Allowance is respectfully requested as soon as possible. If there are any questions regarding these amendments and remarks, or if further discussion would expedite allowance of the claims, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

Date: December 10, 2003

By: Renee S. Polizotto

Renée S. Polizotto, Ph.D.
Agent for Applicants
Registration No.: 53,474
Customer No.: 34285
NUVELO, INC.
675 Almanor Avenue
Sunnyvale, CA 94085
Tel. (408) 215-4000
Fax (408) 524-8145